Minoxidil


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Severe HTN unresponsive to standard therapy In conjunction w/ a β-blocker or methyldopa, and a diuretic: Initial: 5 mg/day, increase gradually at intervals of at least 3 days up to 40 mg or 50 mg as a single or in 2 divided doses daily. Max: 100 mg/day. For rapid control of BP: Dose increments of 5 mg 6 hrly may be given. Topical Male pattern baldness Male: As 2% or 5% soln: Apply 1 mL bid. As 5% foam or aerosol: Apply ½ capful bid. Female: As 2% soln: Apply 1 mL bid. As 5% foam or aerosol: Apply ½ capful once daily.
Dosage Details
Oral
Severe hypertension unresponsive to standard therapy
Adult: In conjunction w/ a β-blocker or methyldopa, and a diuretic: Initially, 5 mg daily, gradually increase at intervals of at least 3 days to 40 mg or 50 mg as a single or in 2 divided doses daily depending on response. Max: 100 mg daily. For rapid control of BP: Dose increments of 5 mg 6 hrly may be given w/ careful monitoring.
Child: ≤12 yr In conjunction w/ a β-blocker or methyldopa, and a diuretic: Initially, 200 mcg/kg daily in 1 or 2 divided doses w/ increments of 100-200 mcg/kg at intervals of at least 3 days according to response. Max: 1 mg/kg or 50 mg daily.
Elderly: Initially, 2.5 mg daily, increase gradually.

Topical/Cutaneous
Male pattern baldness
Adult: Male: As 2% or 5% soln: Apply 1 mL to the scalp bid. As 5% foam or aerosol: Apply ½ capful to the scalp bid. Female: As 2% soln: Apply 1 mL to the scalp bid. As 5% foam or aerosol: Apply ½ capful to the scalp once daily.
Renal Impairment
Oral:
Initiate at smaller doses or at longer dosage intervals.
Administration
May be taken with or without food.
Contraindications
Phaeochromocytoma. Topical: Patient w/ treated or untreated HTN, scalp abnormality (e.g. psoriasis, sunburn), shaved scalp.
Special Precautions
Patient w/ pulmonary HTN, angina pectoris, chronic heart failure, recent MI. Renal impairment. Elderly, childn. Pregnancy and lactation.
Adverse Reactions
Reflex tachycardia, fluid retention, changes in ECG, hypertrichosis, pericardial effusion and tamponade, pericarditis, exacerbation of angina pectoris, headache, nausea, gynaecomastia, breast tenderness, polymenorrhoea, allergic rashes, Stevens-Johnson syndrome. Rarely, thrombocytopenia and leucopenia. Topical: Contact dermatitis, pruritus, local burning, flushing, changes in hair colour or texture.
MonitoringParameters
Monitor BP, fluid and electrolytes, body wt, signs/symptoms of pericardial effusion, renal function.
Overdosage
Symptoms: Exaggerated hypotension. Management: Admin IV normal saline. Phenylephrine, angiotensin II and vasopressin may be given if inadequate perfusion of a vital organ is evident.
Drug Interactions
Additive effect w/ other hypotensive drugs. Risk of orthostatic hypotension w/ sympathetic blocking drugs (e.g. guanethidine). Topical: Enhanced absorption w/ other topical medical preparations (e.g. corticosteroids, retinoids or occlusive ointment bases).
Action
Description: Minoxidil reduces elevated systolic and diastolic BP by decreasing peripheral vascular resistance via vasodilation. Applied topically, it stimulates hair growth secondary to vasodilation, increases cutaneous blood flow and stimulates resting hair follicles.
Onset: Approx 30 min (oral).
Duration: Approx 3 days (oral).
Pharmacokinetics:
Absorption: Approx 90% is absorbed from the GI tract (oral); 0.3-4.5% from intact scalp (topical).
Distribution: Enters breast milk.
Metabolism: Extensively hepatic via glucuronidation.
Excretion: Via urine as metabolites. Elimination half-life: Approx 4.2 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store below 25°C.
Disclaimer: This information is independently developed by MIMS based on Minoxidil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Mandil Forte
  • Minoxidil Isac
  • Regroe
  • Relive
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in